本页汇总 维生素 B12 的 3 篇安全性公开文献，按毒性终点分区，逐条标注研究类型、物种、染毒途径与来源。以上均为各原研究/评估机构的结论，本平台不作再评价，也不构成对该成分的安全性判定。
文献报告了注射氰钴胺（维生素B12）引起的过敏反应，包括痤疮、玫瑰痤疮、过敏部位反应或过敏反应，以及对钴过敏的患者出现慢性水疱性手部皮炎、唇炎和口腔炎等皮肤表现，证实了氰钴胺的致敏风险。
The literature reports allergic reactions to parenteral cyanocobalamin including acne, rosacea, allergic site reactions or anaphylaxis, and cutaneous manifestations in patients with cobalt allergy, confirming the sensitization risk of cyanocobalamin.
该病例报告描述了一名1型糖尿病母亲所生婴儿的全前脑，但婴儿出生后接受了含氰钴胺的补充剂治疗缺铁性贫血，未提及氰钴胺暴露与全前脑的关联；全前脑归因于母体糖尿病，而非氰钴胺。因此，该文献不研究氰钴胺的孕期风险。
This case report describes holoprosencephaly in an infant born to a mother with type 1 diabetes; the infant received cyanocobalamin-containing supplements after birth for iron deficiency anemia, but no association between cyanocobalamin exposure and holoprosencephaly is mentioned; the holoprosencephaly is attributed to maternal diabetes, not cyanocobalamin. Therefore, the article does not study the pregnancy risk of cyanocobalamin.
文献仅提及抗惊厥药升高同型半胱氨酸水平可能解释其致畸作用，但未研究氰钴胺本身的安全性，仅作为维生素B12补充剂提及。
The article only mentions that anticonvulsants raise homocysteine levels, which may explain their teratogenic effects, but does not study cyanocobalamin itself; it is only mentioned as a vitamin B12 supplement.
毒理学实验记录来自标准化的毒性试验（如 OECD 导则试验），给出的是剂量/浓度层面的实验值；公开文献是研究者围绕化妆品实际使用场景发表的研究（本页 3 篇），结论均为原作者观点。两类证据并列呈现，本平台不做合并判定。